大剂量表柔比星治疗非小细胞肺癌的II期研究
Phase II study of high-dose epirubicin in non-small cell lung cancer.
作者信息
Wils J, Utama I, Sala L, Smeets J, Riva A
机构信息
Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands.
出版信息
Eur J Cancer. 1990;26(11-12):1140-1. doi: 10.1016/0277-5379(90)90271-t.
PMID:1963545
Abstract
24 patients with measurable advanced non-small cell lung cancer (NSCLC) were treated with epirubicin 135-150 mg/m2 every 3 weeks. There were 6 partial responses. Randomised studies should reveal whether and how incorporation of epirubicin into combination chemotherapy can enhance outcome in advanced NSCLC.
摘要
24例具有可测量病灶的晚期非小细胞肺癌（NSCLC）患者接受表柔比星治疗，剂量为135 - 150 mg/m²，每3周一次。有6例部分缓解。随机研究应揭示将表柔比星纳入联合化疗是否以及如何能改善晚期NSCLC的治疗结果。
Zotero 插件